High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies.
暂无分享,去创建一个
Yi Li | Henryk Mach | H. Mach | J. Blue | Jeffrey T Blue | Yi Li
[1] Christopher J Roberts,et al. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. , 2010, Journal of pharmaceutical sciences.
[2] Linda O Narhi,et al. High throughput thermostability screening of monoclonal antibody formulations. , 2010, Journal of pharmaceutical sciences.
[3] Babatunde A. Ogunnaike,et al. Multi-variate approach to global protein aggregation behavior and kinetics: effects of pH, NaCl, and temperature for alpha-chymotrypsinogen A. , 2010, Journal of pharmaceutical sciences.
[4] Brian T. Cunningham,et al. A Method for Identifying Small-Molecule Aggregators Using Photonic Crystal Biosensor Microplates , 2009, JALA.
[5] William F. Weiss,et al. Characterization of high-molecular-weight nonnative aggregates and aggregation kinetics by size exclusion chromatography with inline multi-angle laser light scattering. , 2009, Journal of pharmaceutical sciences.
[6] Jared S. Bee,et al. Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies. , 2009, Journal of pharmaceutical sciences.
[7] Hanns-Christian Mahler,et al. Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.
[8] L. Narhi,et al. A critical review of analytical methods for subvisible and visible particles. , 2009, Current pharmaceutical biotechnology.
[9] I. Shimada,et al. High‐throughput screening of optimal solution conditions for structural biological studies by fluorescence correlation spectroscopy , 2009, Protein science : a publication of the Protein Society.
[10] C. Roberts,et al. Lumry-Eyring nucleated-polymerization model of protein aggregation kinetics. 2. Competing growth via condensation and chain polymerization. , 2009, The journal of physical chemistry. B.
[11] Steven Kozlowski,et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. , 2009, Journal of pharmaceutical sciences.
[12] William F Weiss,et al. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. , 2009, Journal of pharmaceutical sciences.
[13] Joon-Seok Lee,et al. High-throughput analysis of Alzheimer's beta-amyloid aggregation using a microfluidic self-assembly of monomers. , 2009, Analytical chemistry.
[14] G. Senisterra,et al. High throughput methods of assessing protein stability and aggregation. , 2009, Molecular bioSystems.
[15] M. Dragunow,et al. High throughput quantification of mutant huntingtin aggregates , 2008, Journal of Neuroscience Methods.
[16] Wim Jiskoot,et al. Extrinsic Fluorescent Dyes as Tools for Protein Characterization , 2008, Pharmaceutical Research.
[17] Christopher J Roberts,et al. Non‐native protein aggregation kinetics , 2007, Biotechnology and bioengineering.
[18] F. Niesen,et al. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.
[19] A. Fink,et al. Fluorescence as a method to reveal structures and membrane-interactions of amyloidogenic proteins. , 2007, Biochimica et biophysica acta.
[20] Christopher J Roberts,et al. A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1. Aggregation with pre-equilibrated unfolding. , 2007, The journal of physical chemistry. B.
[21] C. Roberts,et al. Non-native aggregation of alpha-chymotrypsinogen occurs through nucleation and growth with competing nucleus sizes and negative activation energies. , 2007, Biochemistry.
[22] Robert Gurny,et al. High throughput screening of protein formulation stability: practical considerations. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[23] Robert Gurny,et al. Detection and characterization of protein aggregates by fluorescence microscopy. , 2007, International journal of pharmaceutics.
[24] Randall J Mrsny,et al. Formulation and delivery issues for monoclonal antibody therapeutics. , 2006, Advanced drug delivery reviews.
[25] Dong Jin Kim,et al. A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. , 2006, ACS chemical biology.
[26] M. Lindgren,et al. Detection and characterization of aggregates, prefibrillar amyloidogenic oligomers, and protofibrils using fluorescence spectroscopy. , 2005, Biophysical journal.
[27] Steven J Shire,et al. Challenges in the development of high protein concentration formulations. , 2004, Journal of pharmaceutical sciences.
[28] C. Dobson,et al. Rationalization of the effects of mutations on peptide andprotein aggregation rates , 2003, Nature.
[29] John F. Carpenter,et al. Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation , 2003, Pharmaceutical Research.
[30] Christopher M. Dobson,et al. Kinetic partitioning of protein folding and aggregation , 2002, Nature Structural Biology.
[31] R. Murphy,et al. A mathematical model of the kinetics of beta-amyloid fibril growth from the denatured state. , 2001, Biophysical journal.
[32] R. Carrotta,et al. Conformational characterization of oligomeric intermediates and aggregates in β‐lactoglobulin heat aggregation , 2001, Protein science : a publication of the Protein Society.
[33] V. Uversky,et al. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. , 2001, Biochemistry.
[34] A. Fink. Protein aggregation: folding aggregates, inclusion bodies and amyloid. , 1998, Folding & design.
[35] H. Levine. Stopped-flow kinetics reveal multiple phases of thioflavin T binding to Alzheimer beta (1-40) amyloid fibrils. , 1997, Archives of biochemistry and biophysics.
[36] H J Berger,et al. Practical considerations in the production, purification, and formulation of monoclonal antibodies for immunoscintigraphy and immunotherapy. , 1989, Seminars in nuclear medicine.
[37] Yi Li. Global non-native aggregation behavior for alpha-chymotrypsinogen A , 2009 .
[38] Wei Wang,et al. Antibody structure, instability, and formulation. , 2007, Journal of pharmaceutical sciences.
[39] T. Arakawa,et al. Theory of protein solubility. , 1985, Methods in enzymology.